Eyeforpharma Real World Evidence Conference Round up 2018
Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)
This year has seen a turning point for Japan's pharma industry, as the government and the industry encourage a rapid move towards increased use of RWE from April 2018. Real World Data (RWD) sources provide an unprecedented opportunity for companies to find, demonstrate and communicate their real value to patients, healthcare and society. The conference included topics addressing commercial and medical needs, allowing both communities to come together for the first time encouraging collaboration across functions.
Eyeforpharma – Real World Evidence 2018
16-17 May in Tokyo, Japan
Research Partnership is delighted to be attending the Eyeforpharma Real World Evidence (RWE) conference in Tokyo, Japan 16-17 May. RWE is currently a very hot topic for the Japanese pharma industry, with an increased push to place RWE as a strategic imperative for pharma.
Out of the shadows: Mental health in the Asia Pacific region
Published in eyeforpharma February 2018 by Marc Yates
Mental health has been a peripheral issue in emerging markets for a long time, despite the severe impact it can have, not only on those directly affected but also on families, carers, social cohesion, and economic development. Fortunately, mental health is starting to get more attention, but there is still a widespread tendency to stigmatise and discriminate against people suffering with a mental illness. They are often considered as dangerous and aggressive which in turn increases the social distance.
Is there an opportunity for pharma to do more? In the first of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Asia where problems arising from ill mental health are the second largest contributor to years lost to disability (YL:D).